BACKGROUND: Peritoneal carcinomatosis of colonic origin (PCC) is a life-threatening diagnosis. Cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers patients the prospect of long-term survival with alleviation of symptoms. METHODS: Patients underwent HIPEC for PCC and completed questionnaires preoperatively (T1) and after surgery at 3 (T2), 6 (T3), and 12 (T4) months. Questionnaires included the Functional Assessment of Cancer Therapy-Colon (FACT-C), Brief Pain Inventory (BPI), SF-36 Medical Outcomes Study Survey (SF-36), Center for Epidemiologic Studies-Depression Scale (CES-D), and the ECOG Performance Status Rating. RESULTS: A total of 62 patients were assessed before surgery. Median overall survival was 18 months, with 71.3 ± 6.3% survival at 1 year. Emotional well-being (P = .0007) improved after HIPEC. Social/family well-being (P = .065) and the colon subscale (P = .061) of the FACT worsened at T2, but recovered by T3. One-third to one-half of patients reported depressive symptoms over the course of the study. Pain scores increased above BL at T2, but decreased below BL at T3 and T4. CONCLUSIONS: Emotional well being is improved after CS + HIPEC despite complications that may affect short-term recovery. Most patients remaining in the study recover to preoperative levels of functioning between 3 and 6 months after surgery. For some, survival can be attained without major decrement in QOL at 1 year. QOL concerns must be a key component in the evaluation for patients with PCC for CS and HIPEC.
BACKGROUND:Peritoneal carcinomatosis of colonic origin (PCC) is a life-threatening diagnosis. Cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers patients the prospect of long-term survival with alleviation of symptoms. METHODS:Patients underwent HIPEC for PCC and completed questionnaires preoperatively (T1) and after surgery at 3 (T2), 6 (T3), and 12 (T4) months. Questionnaires included the Functional Assessment of Cancer Therapy-Colon (FACT-C), Brief Pain Inventory (BPI), SF-36 Medical Outcomes Study Survey (SF-36), Center for Epidemiologic Studies-Depression Scale (CES-D), and the ECOG Performance Status Rating. RESULTS: A total of 62 patients were assessed before surgery. Median overall survival was 18 months, with 71.3 ± 6.3% survival at 1 year. Emotional well-being (P = .0007) improved after HIPEC. Social/family well-being (P = .065) and the colon subscale (P = .061) of the FACT worsened at T2, but recovered by T3. One-third to one-half of patients reported depressive symptoms over the course of the study. Pain scores increased above BL at T2, but decreased below BL at T3 and T4. CONCLUSIONS: Emotional well being is improved after CS + HIPEC despite complications that may affect short-term recovery. Most patients remaining in the study recover to preoperative levels of functioning between 3 and 6 months after surgery. For some, survival can be attained without major decrement in QOL at 1 year. QOL concerns must be a key component in the evaluation for patients with PCC for CS and HIPEC.
Authors: Richard P McQuellon; Brian W Loggie; Anna B Lehman; Gregory B Russell; Ronald A Fleming; Perry Shen; Edward A Levine Journal: Ann Surg Oncol Date: 2003-03 Impact factor: 5.344
Authors: A J Witkamp; E de Bree; M M Kaag; H Boot; J H Beijnen; G W van Slooten; F van Coevorden; F A Zoetmulder Journal: Eur J Cancer Date: 2001-05 Impact factor: 9.162
Authors: A C Beaujard; O Glehen; J L Caillot; Y Francois; J Bienvenu; G Panteix; F Garbit; E Grandclément; J Vignal; F N Gilly Journal: Cancer Date: 2000-06-01 Impact factor: 6.860
Authors: Thomas Anthony; Joshua Long; Linda S Hynan; George A Sarosi; Fiemu Nwariaku; James Huth; Charlene Jones; Betty J N Parker; Robert Rege Journal: Surgery Date: 2003-08 Impact factor: 3.982
Authors: Perry Shen; Jason Hawksworth; James Lovato; Brian W Loggie; Kim R Geisinger; Ronald A Fleming; Edward A Levine Journal: Ann Surg Oncol Date: 2004-02 Impact factor: 5.344
Authors: David T Eton; Diane L Fairclough; David Cella; Susan E Yount; Philip Bonomi; David H Johnson Journal: J Clin Oncol Date: 2003-04-15 Impact factor: 44.544
Authors: Dominique Elias; Jean-Robert Delperro; Lucas Sideris; Ellen Benhamou; Marc Pocard; Olivier Baton; Marc Giovannini; Philippe Lasser Journal: Ann Surg Oncol Date: 2004-05 Impact factor: 5.344
Authors: Rebecca M Dodson; Richard P McQuellon; Harveshp D Mogal; Katharine E Duckworth; Gregory B Russell; Konstantinos I Votanopoulos; Perry Shen; Edward A Levine Journal: Ann Surg Oncol Date: 2016-09-08 Impact factor: 5.344
Authors: Yasmin M Ali; Joseph Sweeney; Perry Shen; Konstantinos I Votanopoulos; Richard McQuellon; Katie Duckworth; Kathleen C Perry; Greg Russell; Edward A Levine Journal: Ann Surg Oncol Date: 2019-05-08 Impact factor: 5.344
Authors: Patrick L Wagner; Frances Austin; Ugwuji Maduekwe; Arun Mavanur; Lekshmi Ramalingam; Heather L Jones; Matthew P Holtzman; Steven A Ahrendt; Amer H Zureikat; James F Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry Journal: Ann Surg Oncol Date: 2013-03-02 Impact factor: 5.344
Authors: Reese W Randle; Katrina R Swett; Perry Shen; John H Stewart; Edward A Levine; Konstantinos I Votanopoulos Journal: Am Surg Date: 2013-06 Impact factor: 0.688
Authors: Reese W Randle; Katrina R Swett; Douglas S Swords; Perry Shen; John H Stewart; Edward A Levine; Konstantinos I Votanopoulos Journal: Ann Surg Oncol Date: 2013-08-28 Impact factor: 5.344
Authors: Carissa A Low; Dana H Bovbjerg; Frank J Jenkins; Steven A Ahrendt; Haroon A Choudry; Matthew P Holtzman; Heather L Jones; James F Pingpank; Lekshmi Ramalingam; Herbert J Zeh; Amer H Zureikat; David L Bartlett Journal: Brain Behav Immun Date: 2014-07-06 Impact factor: 7.217